← boardnext 2028-02
WHWK
Whitehawk Therapeutics, Inc.distress 3/10 · well-funded / low risk$3.77-6%today-26% from 52w high
Lead: Endometrial Cancer
Revenue
pre-revenue
Liquidity
$123M
Runway
1.1 yrs
Shares 1y
+5%
Price & events
+32.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-5.5%
1D
-3.1%
1W
-13.7%
1M
-9.6%
3M
+39.6%
6M
+87.6%
1Y
+140.1%
2Y
-87.9%
5Y
-76.1%
All
Overview
- Market Cap
- $186.44M
- Volume
- 32.69K
- 52 Week Range
- $1.60 – $5.10
- Total Shares
- 49.45M
- Float Shares
- 20.59M
- Short %
- 10.20%
- % Held by Insiders
- 13.38%
- % Held by Institutions
- 72.78%
- RVOL
- 0.06x
- Beta
- 0.77
Pipeline stages · 1 programs
HWK-007
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-02 Estimated 50% readout ~2028-03-02 | Phase 1 | HWK-016, MUCIN-16-targeted ADC, Bevacizumab | PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer | — | recruiting |
| 2028-10 Estimated 50% readout ~2028-10-31 | Phase 1 | HWK-007 | Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC | — | recruiting |
Catalyst news & presentations · 7
- over the next 12-24 monthsGuided 40%regulatory submissionFiled (NDA/BLA)multiple new ADC programs · IND submissions for multiple new ADC programs from option agreement.SEC 8-K
- first half of 2027Guided 55%readoutPhase 1HWK-007 · Initial Phase 1 data from dose-escalation trial.SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-year 2026regulatory submissionFiled (NDA/BLA)HWK-206 · IND submission anticipated mid-year 2026.SEC 8-K
- May 30, 2026, 1:30-4:30 PM CDTconferencedata presentationsecondaryPhase 1HWK-007 · Trials-in-Progress poster presentation of Phase 1 study of HWK-007 at ASCO.SEC 8-K
- 2026-05-21partnershipmultiple · Option agreement with Hangzhou DAC for CPT113 linker-payload for up to five additional ADC programs.SEC 8-K
- 2024-09-26partnershipArbitration panel ruled company did not breach license agreementSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $8 (+99% upside) · 6 analysts
- 2026-07-13Leerink PartnersOutperform
- 2026-06-25B. Riley SecuritiesBuy
- 2026-04-16CitizensMarket Outperform
- 2025-12-22Jones TradingBuy
Competitors — Endometrial Cancer
- MRKMerck & Co., Inc.$318.8B · D3
- PFEPFIZER INC$142.2B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- XNCRXencor Inc$1.4B · D4
- MGNXMACROGENICS INC$263M · D4
- KPTIKaryopharm Therapeutics Inc.$157M · D7
- ACRVAcrivon Therapeutics, Inc.$72M · D3
- RDPTFRadiopharm Theranostics Ltd$24M · D3
- NXTCNextCure, Inc.$16M · D9
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-18Whitehawk Therapeutics (WHWK) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary - Quartr
- 2026-07-14Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest - MarketBeat
- 2026-07-13WHWK Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
- 2026-07-13Price to book forward of Whitehawk Therapeutics, Inc. – HAM:3350 - TradingView
- 2026-07-08Whitehawk Therapeutics (WHWK) Jefferies 2024 Global Healthcare Conference Summary - Quartr
- 2026-07-08Whitehawk Therapeutics (WHWK) Q4 2024 earnings summary - Quartr
- 2026-07-07Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development - Business Wire
- 2026-07-07Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.